GlassScriptPhysician profile
Merl Simmons
NPI 1558391466
$534.44
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $492 · 2020: $42.61.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $126.19 | 2019 | |
| Amgen INC. | $74.54 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.93 | 2019 | |
| Amarin Pharma, INC. | $39.34 | 2019 | |
| Ironshore Pharmaceuticals INC. | $36.11 | 2019 | |
| Shire North American Group INC | $33.96 | 2019 | |
| Novo Nordisk INC | $32.03 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $24.55 | 2019 | |
| Merck Sharp & Dohme LLC | $23.25 | 2019 | |
| Glaxosmithkline, LLC. | $17.05 | 2020 | |
| Abbvie INC. | $16.70 | 2019 | |
| Neos Therapeutics, LP | $16.02 | 2019 | |
| Pfizer INC. | $13.59 | 2020 | |
| Upsher-Smith Laboratories LLC | $12.80 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.41 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $11.97 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Merl Simmons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.